Meeting Overview - The shareholders' meeting was held on December 18, 2025, at the company's conference room in Tianjin [2] - The meeting was conducted with a combination of on-site and online voting, presided over by the company's president, as the chairman was absent [2][3] Attendance - Out of 9 current directors, 7 attended the meeting, while 3 supervisors were present [3] - Some directors and supervisors attended via video conference [4] Resolutions Passed - The following resolutions were approved: 1. Cancellation of the supervisory board [5] 2. Abolishment of the "Supervisory Meeting Rules" [5] 3. Change of business scope [6] 4. Revision of the company's articles of association [6] 5. Revision of certain governance systems [6] 6. Approval of estimated daily related party transaction limits for 2026 [6] 7. Approval of comprehensive credit limits and guarantees for wholly-owned subsidiaries for 2026 [6] 8. Appointment of the auditing firm for 2025 [6] Voting Results - Resolutions 4 and 7 were special resolutions, requiring more than two-thirds of the votes from present shareholders [7] - Resolutions 1, 2, 3, 5, 6, and 8 were ordinary resolutions, requiring more than half of the votes from present shareholders [7] - Related party transaction resolution involved a shareholder who abstained from voting [7] Legal Verification - The meeting was witnessed by Beijing Zhonglun Law Firm, confirming that the meeting's procedures complied with legal and regulatory requirements [7]

注：控股股东及一致行动人持股比例从64.48%被动变为62.69%。 一、股权激励计划前期基本情况 海利尔药业集团股份有限公司（以下简称"公司"）2025年限制性股票激励计划（以下简称"本次激励计 划"）方式为___限制性股票_，股份来源为_公司向激励对象定向发行公司A股普通股_，拟授予的权益 数量为_1,250.00万股__，占公司总股本比例为__3.68%____。其中，首次授予的权益数量为_1,150.00万 股_____，占公司总股本比例为__3.38%____；预留授予的权益数量为__100.00万股____，占公司总股本 比例为__0.29%____。具体内容详见公司2025年9月30日披露于上海证券交易所官网（www.sse.com.cn） 的《海利尔药业集团股份有限公司2025年限制性股票激励计划（草案）摘要公告》（公告编号：2025- 048）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 二、限制性股票授予情况 （一）本次权益授予的具体情况 ■ 5、股票来源：公司向激励对象定向发行本 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 索通发展股份有限公司（以下简称"公司"或"索通发展"）于近期收到上海证券交易所上市公司管理一部 《关于索通发展股份有限公司境外投资相关董事会决议存在弃权票的监管工作函》（上证公函【2025】 4048号）（以下简称"《工作函》"）。公司收到《工作函》后高度重视，积极组织相关部门对《工作 函》所涉及问题进行全面核实和分析，现就《工作函》有关问题回复如下： 一、根据公告，公司先后在2023年6月、2025年5月披露与EGA公司签署《投资谅解备忘录》《联合开 发协议》，本次双方签署《合资协议》系投资进展。公司披露称，阳极生产厂的建设将于2026年第二/ 三季度开始，并在2028年第二/三季度末开始商业化生产，但未详细披露该投资项目的建设工期，以及 具体的经济效益等。 请公司补充披露：（1）阳极生产厂项目的后续建设安排，包括各项投资项目的金额、建设周期、资金 来源等；（2）阳极生产厂项目经营达成后预计效益的测算过程，包括但不限于预计实现的 ...

一般项目：家具制造;家具零配件生产;家具销售;家具零配件销售;家具安装和维修服务;木材加工;人造板 制造;地板制造;楼梯制造;建筑用木料及木材组件加工;门窗制造加工;门窗销售;室内木门窗安装服务;金属 门窗工程施工;卫生洁具制造;卫生洁具销售;卫生洁具研发;卫生陶瓷制品制造;卫生陶瓷制品销售;厨具卫 具及日用杂品批发;厨具卫具及日用杂品零售;厨具卫具及日用杂品研发;玻璃制造;日用玻璃制品制造;日 用玻璃制品销售;家居用品制造;家居用品销售;日用杂品制造;五金产品制造;五金产品批发;五金产品零售; 五金产品研发;家用纺织制成品制造;家用电器制造;家用电器销售;家用电器研发;家用电器零配件销售;家 用电器安装服务;照明器具制造;照明器具销售;日用百货销售;建筑装饰材料销售;运输货物打包服务;普通 货物仓储服务（不含危险化学品等需许可审批的项目）;国内货物运输代理;装卸搬运;专业设计服务;工 业设计服务;工业工程设计服务;软件开发;软件销售;互联网销售（除销售需要许可的商品）;货物进出口; 技术进出口 ■ 二、欧派集成本次变更后的工商登记信息情况 欧派集成换发后的《营业执照》登记的主要信息如下： 1、名称：广州欧派 ...

Core Viewpoint - Ningbo Meinuohua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the raw material drug Atorvastatin Calcium, which will enhance the company's product line and business scope [1][3]. Group 1: Registration Information - The registration number for Atorvastatin Calcium is Y20240000440, and it is produced by Xuancheng Meinuohua Pharmaceutical Co., Ltd. in Anhui [1]. - The product is available in various packaging specifications: 5kg, 10kg, 15kg, 20kg, and 25kg [1]. - The approval indicates that the product meets the requirements for drug registration under the Drug Administration Law of the People's Republic of China [1]. Group 2: Indications and Pharmacological Action - Atorvastatin Calcium is indicated for the treatment of hypercholesterolemia and mixed hyperlipidemia, as well as for the prevention and treatment of coronary heart disease [2]. - The drug functions as a statin, primarily acting in the liver to reduce cholesterol synthesis, increase low-density lipoprotein receptor synthesis, lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately decrease serum triglyceride levels, and increase high-density lipoprotein levels [2]. Group 3: Impact on the Company - Xuancheng Meinuohua submitted the review application for Atorvastatin Calcium on May 16, 2024, and it passed the review on December 17, 2025, with a cumulative R&D investment of 14.9496 million yuan [3]. - The approval of Atorvastatin Calcium demonstrates compliance with national drug review technical standards, allowing the product to be sold in the domestic market, which will enrich the subsidiary's product line and help expand the company's business scope [3].

Group 1 - The court will conduct a public auction for 10,470,610 shares of Jiangxi Mubang High-Tech Co., Ltd. (stock code: 603398) held by Jiangxi Mubang New Energy Holdings Co., Ltd. on January 26-27, 2026 [1] - The starting price for the auction is set at 76,058,511.04 yuan, calculated as 80% of the average closing price over the last 20 trading days prior to December 16, 2025, multiplied by the total number of shares [1] - A deposit of 7,605,851 yuan is required to participate in the auction, with a minimum bid increment of 380,292 yuan [1] Group 2 - Legal and regulatory restrictions prevent certain entities from participating in the auction, including those prohibited from holding or trading shares of listed companies [2] - Bidders and their concerted actions must not exceed 30% of the total issued shares of the company; if they do, they must comply with relevant securities laws and report to the court [2]

Core Viewpoint - The CRH380D train brake pads have passed small-scale testing, allowing the product to participate in market competition, but this does not guarantee market orders or direct contributions to performance [1][3]. Group 1: Product Testing and Qualification - The CRH380D train brake pads underwent small-scale testing from October 30, 2024, to November 12, 2025, and the overall operational status was good, meeting the testing requirements [1]. - The product is now qualified for market sales, marking an extension of the company's train braking products to the 300-350 km/h speed range, which enhances the product matrix in the rail transportation sector [2]. Group 2: Impact on Company Operations and Performance - The small-scale testing of the CRH380D train brake pads does not directly correlate with market orders or performance contributions, as sales and performance will depend on specific orders or contract execution [3]. - While the new product's qualification is expected to positively influence market expansion and future operational performance, it will not significantly impact the company's current year operating results [3].

Meeting Overview - The shareholder meeting was held on December 18, 2025, at the company's conference room in Shenzhen [1] - The meeting was chaired by Chairman Lu Hongyan, and all procedures complied with the Company Law and Articles of Association [1] Attendance - All 8 current directors attended the meeting, including 3 independent directors and 1 employee director [1] - The company secretary and all senior management were present as well [1] Resolutions Passed - The proposal for the "Shareholder Return Plan for the Next Three Years (2025-2027)" was approved [1] - The proposal for the "Director Remuneration Management System" was also approved [1] - All resolutions were ordinary resolutions and passed with more than half of the voting rights held by attending shareholders [1] Legal Verification - The meeting was witnessed by Beijing Haiwen (Shenzhen) Law Firm, with lawyers Li Liping and Li Jun'e providing legal opinions [2] - The legal opinion confirmed that the meeting's procedures and voting were in compliance with relevant laws and the company's regulations, validating the voting results [2] Announcement - A legal opinion signed and stamped by the law firm's director will be made available online [3]

一、同意公司向专业投资者公开发行面值总额不超过20亿元公司债券的注册申请。 二、本次发行公司债券应严格按照报送上海证券交易所的募集说明书进行。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600739 证券简称：辽宁成大 公告编号：2025－085 辽宁成大股份有限公司 关于向专业投资者公开发行公司债券获得中国证监会同意注册批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司（以下简称"公司"）收到中国证券监督管理委员会出具的《关于同意辽宁成大股 份有限公司向专业投资者公开发行公司债券注册的批复》（证监许可[2025]2765号），批复内容如下： 三、本批复自同意注册之日起24个月内有效，公司在注册有效期内可以分期发行公司债券。 四、自同意注册之日起至本次公司债券发行结束前，公司如发生重大事项，应及时报告并按有关规定处 理。 公司将按照相关法律、法规和上述批复文件的要求，在公司股东会的授权范围内办理本次发行公司债券 的相关事宜，并及时履行相关信息披露义务。 特此公告。 辽宁成大股份有 ...

证券代码：600711 证券简称：盛屯矿业 公告编号：2025-076 盛屯矿业集团股份有限公司 关于控股股东部分股份解质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 公司于近日接到公司控股股东深圳盛屯集团的通知，获悉其将持有的公司股份进行了解除质押，具体情 况如下： ■ 经与公司控股股东确认，本次解除质押的股份后续是否会用于质押尚不确定。截至本公告日，公司控股 股东所质押的股份不存在平仓风险。 特此公告。 盛屯矿业集团股份有限公司 董事会 2025年12月19日 重要内容提示： ●盛屯矿业集团股份有限公司（以下简称"公司"或"盛屯矿业"）控股股东深圳盛屯集团有限公司（以下 简称"深圳盛屯集团"）持有公司股份457,494,897股，占公司股份总数的14.80%；公司实际控制人姚雄杰 先生持有公司股份40,305,000股，占公司股份总数的1.30%。 ●截至本公告披露日，公司控股股东、实际控制人及其一致行动人累计持有公司股份数量为554,799,897 股，占公司总股本比例为17.95%；本次股份解质押后，公司控 ...